奥希替尼联合萨沃替尼为晚期 EGFR 突变 NSCLC 合并 MET 异常患者带来生存获益
Posted inClinical Updates Oncology Respiratory

Enhanced Survival with Osimertinib and Savolitinib Combination in Advanced EGFR-Mutated NSCLC with MET Dysregulation Post-Osimertinib Progression

The phase 3 SAFFRON trial demonstrated that osimertinib combined with savolitinib significantly improves progression-free and overall survival versus platinum-pemetrexed chemotherapy in advanced EGFR-mutated NSCLC harboring MET overexpression or amplification after osimertinib failure.
Evaluating the Impact of Multicancer Early-Detection Blood Tests on Late-Stage Cancer Diagnosis: Insights from a Large Randomized Trial
Posted innews Oncology Public Health

Evaluating the Impact of Multicancer Early-Detection Blood Tests on Late-Stage Cancer Diagnosis: Insights from a Large Randomized Trial

A large randomized trial assessing whether adding a blood-based multicancer early-detection test to usual care reduces late-stage cancer diagnoses found no significant difference in stage III or IV cancers but observed a trend toward fewer stage IV cancers after three screening rounds.
Therapeutic Hypothermia at 35°C vs. Controlled Normothermia in ICU Heatstroke: Insights from a Pilot RCT
Posted inCritical Care Emergency Medicine news

Therapeutic Hypothermia at 35°C vs. Controlled Normothermia in ICU Heatstroke: Insights from a Pilot RCT

A pilot randomized trial comparing targeted temperature management at 35°C versus normothermia in intubated heatstroke patients showed no survival or neurological benefit from hypothermia but increased gastrointestinal injury and arrhythmias, highlighting safety concerns and questioning routine hypothermia use in this setting.